8-K: Disc Medicine Announces Positive Clinical Data Across Portfolio at EHA 2024 Congress

Disc Medicine presented updated clinical data for bitopertin in EPP, DISC-0974 in MF anemia, and initial data for DISC-3405 in healthy volunteers at the European Hematology Association 2024 Congress.

Summary

• Disc Medicine announced updated data from its clinical trials at the European Hematology Association 2024 Congress.
• The company presented updated analyses from the Phase 2 AURORA and BEACON trials for bitopertin in erythropoietic protoporphyria (EPP).
• The AURORA study showed a 40% reduction in protoporphyrin IX (PPIX) levels in the 60 mg bitopertin group compared to placebo.
• Both 20 mg and 60 mg bitopertin groups showed a two-fold improvement in light tolerance relative to baseline.
• The 60 mg bitopertin group had a 75.3% reduction in phototoxic reactions compared to placebo.
• The BEACON study results were consistent with previous data, showing similar clinical activity to AURORA.
• Updated data from the Phase 1b study of DISC-0974 in myelofibrosis (MF) anemia showed a 68.9% hemoglobin response rate in non-transfusion dependent participants.
• 60% of non-transfusion dependent participants had a mean hemoglobin response of 1.5 g/dL above baseline sustained for at least 12 weeks.
• One of two evaluable transfusion dependent participants became transfusion independent.
• All evaluable participants with baseline transfusion requirements demonstrated at least a 50% reduction in transfusions.
• Initial data from the Phase 1 study of DISC-3405 in healthy volunteers showed a dose-dependent increase in hepcidin and a reduction in serum iron.
• Mean serum iron reduction exceeded 50% from baseline in the 150and 300-mg dose groups.
• The 300-mg dose group sustained a mean serum iron reduction of over 50% for at least 4 weeks.

Sentiment

Score: 9

Explanation: The document presents very positive clinical data across multiple programs, with strong efficacy and safety signals. The management commentary is also very positive, and the future outlook is promising. The overall tone is very optimistic and suggests a high likelihood of success for the company's pipeline.

Positives

• Bitopertin demonstrated significant reductions in PPIX levels and improvements in light tolerance and phototoxic reactions in EPP patients.
• DISC-0974 showed strong hematologic responses in MF patients, including increased hemoglobin levels and reduced transfusion needs.
• DISC-3405 demonstrated a dose-dependent increase in hepcidin and reduction in serum iron, supporting its potential as an iron restriction agent.
• All three investigational agents were generally well-tolerated with no serious adverse events reported to date.
• The data supports the continued development of all three programs.

Negatives

• The AURORA study did not meet statistical significance for the primary endpoint of cumulative time in light without pain due to strong performance of the placebo arm.
• One participant in the DISC-3405 study was excluded from the analysis due to a pre-existing condition not disclosed prior to enrollment.
• Some participants experienced mild adverse events such as dizziness, nausea, and headache.

Risks

• The investigational agents are not approved for use as therapies in any jurisdiction worldwide.
• Clinical trial results may not be predictive of future results.
• The company faces risks related to the adequacy of capital to support future operations and the ability to successfully complete clinical trials.
• There are risks associated with the timing of initiation and availability of data from clinical trials.
• The company may not be able to identify additional product candidates with significant commercial potential.

Future Outlook

Disc Medicine anticipates multiple data catalysts through the rest of the year, including end of Phase 2 meetings for bitopertin and DISC-0974, initiation of a Phase 3 study for bitopertin in EPP and XLP, and a Phase 2 study for DISC-0974 in MF. Phase 1 multiple-ascending dose (MAD) data for DISC-3405 is expected by the end of the year, with a Phase 2 study in polycythemia vera expected in the first half of 2025. The company believes it has capital to fund operations well into 2026.

Management Comments

• John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc, stated that this has been a tremendously exciting EHA meeting for Disc.
• He also mentioned that the company shared a deeper analysis of data from AURORA that underscores their confidence in bitopertin's potential in EPP.
• He noted that the company provided an update from their study of DISC-0974 in anemia of myelofibrosis, which continues to demonstrate promising hematologic activity.
• He also stated that they were excited to share data from their third program, DISC-3405, in healthy volunteers, demonstrating clinical proof-of-mechanism.

Industry Context

The announcement highlights Disc Medicine's progress in developing novel treatments for hematologic diseases, positioning them as a key player in the biopharmaceutical space. The data presented at EHA 2024 Congress is significant for the rare disease community, particularly for EPP and MF patients, where there are limited treatment options. The company's focus on heme biosynthesis and iron homeostasis aligns with current trends in hematology research.

Comparison to Industry Standards

• The 40% reduction in PPIX levels with bitopertin in the AURORA trial is comparable to or better than results seen with other experimental therapies for EPP.
• The 68.9% hemoglobin response rate in non-transfusion dependent MF patients with DISC-0974 is competitive with other emerging treatments for MF anemia.
• The sustained reduction in serum iron with DISC-3405 is a promising result compared to other iron restriction agents in development.
• The safety profiles of all three investigational agents appear favorable compared to other drugs in similar stages of development.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and future outlook.
• Employees may feel more confident in the company's prospects and their job security.
• Patients with EPP, MF anemia, and other hematologic diseases may have increased hope for new treatment options.
• Suppliers and creditors may view the company as a more reliable partner due to the positive clinical results.

Next Steps

• Disc Medicine will have an end of Phase 2 meeting with regulators in the second half of 2024 for bitopertin.
• The company plans to initiate a pivotal study for bitopertin in EPP and XLP in the first half of 2025.
• Disc Medicine will have an end of Phase 1b meeting with regulators in the second half of 2024 for DISC-0974.
• The company plans to initiate a Phase 2 study for DISC-0974 in MF by the end of 2024.
• Phase 1 multiple-ascending dose (MAD) data for DISC-3405 is expected by the end of the year.
• The company plans to initiate a Phase 2 study for DISC-3405 in polycythemia vera in the first half of 2025.

Key Dates

Keywords

bitopertin, DISC-0974, DISC-3405, erythropoietic protoporphyria, myelofibrosis, anemia, hepcidin, iron, clinical trial, hematology